Clinical Trials Logo

Filter by:
NCT ID: NCT06183736 Not yet recruiting - Clinical trials for Advanced Solid Tumors

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.

NCT ID: NCT06183658 Recruiting - Alzheimer's Disease Clinical Trials

Greater-Bay-Area Healthy Aging Brain Study (GHABS)

GHABS
Start date: May 1, 2021
Phase:
Study type: Observational

The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows: 1. The prevalence and characteristics of AD in South China's aging population 2. Identify novel biomarkers and neuroimaging techniques for early detection and intervention of AD 3. Supporting and fertilizing novel approaches and techniques for early diagnosis and intervention of AD Participants will undergo cognitive assessments, blood sample collection, and genetic testing. Some will undergo CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning.

NCT ID: NCT06183554 Recruiting - Clinical trials for Primary Aldosteronism

CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism

Start date: August 31, 2023
Phase:
Study type: Observational

This study aimed to prospectively evaluate the utility of C-X-C chemokine receptor type 4 (CXCR4) positron emission tomography (PET) imaging in patients with clinical suspected primary aldosteronism (PA), with postoperative pathological or follow-up results as reference standards.

NCT ID: NCT06183216 Recruiting - Clinical trials for Pneumococcal Infectious Disease

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Start date: January 4, 2024
Phase: Phase 1
Study type: Interventional

A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.

NCT ID: NCT06183138 Recruiting - Hereditary Diseases Clinical Trials

Multicenter Analysis of Genomic and Metabolic Data of Neonatal Genetic Diseases

MAOFGAMDNGD
Start date: September 1, 2022
Phase:
Study type: Observational

object name: Multicenter analysis of genomic and metabolic data of neonatal genetic diseases. goal of study:(1) Gene sequencing data (138 genes related to 133 common genetic diseases) and tandem mass spectrometry metabolomics data (11 amino acids and 28 acylcarnitines) of about 40,000 newborns from the South China Neonatal Genetic Screening Alliance participating units were collected and collated to complete the database construction of genes and mass spectrometry. (2) Explore the use of genome and metabolome big data and machine learning algorithms such as Random forest, Support Vector Machine, Elastic net, Multilayer Perceptron to construct prediction models for common genetic diseases, and strive to achieve accurate diagnosis and prediction of common genetic diseases using simple tandem mass spectrometry metabolome data, and expand the application range of tandem mass spectrometry technology for disease detection. research design:retrospective observational study Research period:September 2022 to December 2025 Participating units:South China Neonatal genetic screening Alliance (including cooperation units of 123 hospitals) research object:Gene screening data of 40,000 newborns ( 138 genes related to 133 common genetic diseases ) and tandem mass spectrometry data ( 11 amino acids and 28 acylcarnitines ). Inclusion criteria:( 1 ) Newborns who underwent genetic screening and tandem mass spectrometry at the same time. ( 2 ) Age : 0-28 days, gestational age 37-42 weeks. Excluded criteria:Data that meets any of the following conditions need to be eliminated : ( 1 ) Neonatal data with unclear clinical basic information ; ( 2 ) Lack of traceability core information data ; ( 3 ) The data that the test results cannot be analyzed and interpreted. data collection:( 1 ) Basic information : gender, age, sample type, subject traceability number / ID number, etc. ( 2 ) Clinical symptoms, biochemical and imaging data of positive samples. ( 3 ) Gene detection results and tandem mass spectrometry results. ( 4 ) Date of test data, instrument model, reagent type, etc.

NCT ID: NCT06183060 Recruiting - Difficult Airway Clinical Trials

Study on the Decision Support System of Difficult Airway Evaluation

Start date: March 21, 2022
Phase:
Study type: Observational

Based on the evaluation of preoperative physical indicators and radiologic indicators of cervical surgery, this study puts forward effective indicators for predicting difficult airway before operation, and establishes a comprehensive decision support system of difficult airway evaluation, so as to provide a theoretical basis for the early warning of difficult airway before cervical spondylosis surgery.

NCT ID: NCT06182969 Not yet recruiting - SLE Clinical Trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

NCT ID: NCT06182943 Recruiting - Electroacupuncture Clinical Trials

Clinical Evaluation of Surrounding Electroacupuncture in the Treatment of Acute Lateral Ankle Sprain

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

Comparison and evaluation of the difference in clinical efficacy of electroacupuncture combined with surrounding acupuncture and sham electroacupuncture groups and control group (ice compress combined with brake rest group) in the treatment of ALAS by means of musculoskeletal ultrasound technique.

NCT ID: NCT06182917 Recruiting - Ovarian Cancer Clinical Trials

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Start date: October 1, 2023
Phase:
Study type: Observational [Patient Registry]

Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with ovarian cancer have low CA125 expression. Therefore, CA125 is not sensitive to some ovarian cancers with a high risk of recurrence. How to improve the diagnostic performance of these CA125-insensitive patients is a difficult problem in current research. Minimal residual disease (MRD) refers to the residual tumor components in the body of tumor patients after achieving complete remission through treatment. MRD detection is mainly achieved by liquid biopsy, and residual tumor components can be detected by circulating tumor DNA (ctDNA). This study aims to explore the value of MRD (ctDNA) in the risk assessment of CA125 non sensitive ovarian cancer populations by combining ctDNA with traditional imaging and serological tumor markers.

NCT ID: NCT06182891 Completed - Clinical trials for Type 2 Diabetic Nephropathy

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Start date: October 30, 2021
Phase: N/A
Study type: Interventional

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.